It has been confirmed that SGI-110 is able to improve the expression of HLA class I molecule on melanoma cells and the number of CD8+ T cells and CD20+ B cells, which demonstrated that SGI-110 has promising immunomodulatory and antitumor capacity (153). Here, CD8A is linked to melanoma.